Gary Sender
CIK 1659085 · Chief Financial Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$401.0K
Companies
4
Total Filings
44
Lifetime Open-Market Net
-$1.87M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SDGR | Director | 25,388 | $15.29 | $388.2K | -$1.91M | 8 | 2026-06-23 |
| HRMY | Director | — | $35.77 | — | $0 | 7 | 2026-05-18 |
| IBIO | Director | 9,191 | $1.39 | $12.8K | $25.0K | 5 | 2025-11-24 |
| Nabriva Therapeutics plc (NBRV) Delisted | Chief Financial Officer | 819 | $1.42 | $1.2K | $18.5K | 23 | 2021-03-02 |
Recent Filings · Page 4 of 5
44 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-04 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −301 | -$165 | EDGAR |
| 2020-04-02 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −301 | -$173 | EDGAR |
| 2020-03-03 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −301 | -$406 | EDGAR |
| 2020-02-10 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | +105,000 | $0 | EDGAR |
| 2020-02-10 | SDGR | Grant (A) | — | $0 | EDGAR |
| 2020-02-04 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −4,295 | -$5.8K | EDGAR |
| 2019-08-26 | Nabriva Therapeutics plc (NBRV) Delisted | Sell (S) | −3,390 | -$7.1K | EDGAR |
| 2019-08-21 | Nabriva Therapeutics plc (NBRV) Delisted | Mixed | +7,860 | -$7.1K | EDGAR |
| 2019-02-04 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-23 | Nabriva Therapeutics plc (NBRV) Delisted | Buy (P) | +2,000 | $9.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.